Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
$1.03
+3.0%
$0.90
$0.41
$6.59
$4.54M-0.1737,811 shs313 shs
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$1.62
-3.6%
$1.75
$1.21
$2.55
$12.16M76.75167,035 shs112,404 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.33
$0.25
$1.20
$17.03M1.19170,191 shs4.12 million shs
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$1.92
-5.4%
$1.88
$1.32
$7.66
$9.92M2.75212,674 shs79,549 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
0.00%0.00%+11.11%-20.00%-76.15%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
0.00%-6.93%+4.35%+0.60%-9.19%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-31.43%-71.98%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00%-0.49%+38.10%-44.23%-97.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
N/AN/AN/AN/AN/AN/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
4.008 of 5 stars
3.55.00.00.03.23.31.3
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.51 of 5 stars
0.03.00.00.02.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
0.00
N/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
3.00
Buy$18.001,011.11% Upside
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
$741.86M0.01$5.42 per share0.19($23.96) per share-0.04
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$391K31.09N/AN/A$2.45 per share0.66
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$511.08K19.42N/AN/A$0.54 per share3.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
-$69.79M-$19.42N/AN/A-7.79%N/A-3.87%8/4/2025 (Estimated)
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$14.41M-$1.47N/AN/AN/A-2,697.08%-98.49%-75.23%8/12/2025 (Estimated)
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
-$9.21M-$4.64N/AN/A-1,237.00%-138.00%-118.88%N/A

Latest ATIP, ENZ, BRTX, and MGRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.29N/A-$1.29N/A$0.11 million
5/14/2025Q1 2025
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million
3/27/2025Q4 2024
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million
3/20/2025Q4 2024
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.01N/A-$1.01N/A$0.11 million
3/17/2025Q2 2025
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A-$0.02N/A-$0.03N/A$7.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
N/AN/AN/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
N/A
1.12
1.12
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/A
2.95
2.95
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A
0.07
0.07

Institutional Ownership

CompanyInstitutional Ownership
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
72.60%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
69.38%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
56.72%

Insider Ownership

CompanyInsider Ownership
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
3.30%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
25.50%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
5,6004.41 million4.27 millionNo Data
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
77.51 million5.16 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
35.17 million1.51 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATI Physical Therapy stock logo

ATI Physical Therapy NYSE:ATIP

$1.03 +0.03 (+3.00%)
As of 11:05 AM Eastern

ATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work injury rehabilitation services, work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity evaluation, sports medicine, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in therapy treatments; and sports medicine, including on-site sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI brand name. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.

BioRestorative Therapies stock logo

BioRestorative Therapies NASDAQ:BRTX

$1.62 -0.06 (-3.57%)
Closing price 04:00 PM Eastern
Extended Trading
$1.64 +0.02 (+0.99%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Mangoceuticals stock logo

Mangoceuticals NASDAQ:MGRX

$1.92 -0.11 (-5.42%)
Closing price 04:00 PM Eastern
Extended Trading
$1.92 0.00 (0.00%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.